favipiravir and Bone-Neoplasms

favipiravir has been researched along with Bone-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for favipiravir and Bone-Neoplasms

Article	Year
A possible interaction between favipiravir and methotrexate: Drug-induced hepatotoxicity in a patient with osteosarcoma. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:2 Favipiravir is an antiviral agent that is recently used for SARS-CoV2 infection. The drug-drug interactions of favipiravir especially with chemotherapeutic agents in a patient with malignancy are not well known.. Favipiravir may inhibit methotrexate elimination by inhibiting aldehyde oxidase and its sequential use may cause hepatotoxicity in this case. The clinicians should keep in mind possible drug interactions while using new antiviral agents against SARS-CoV2 like favipiravir. Topics: Amides; Antiviral Agents; Bone Neoplasms; Chemical and Drug Induced Liver Injury; COVID-19; Humans; Methotrexate; Osteosarcoma; Pharmaceutical Preparations; Pyrazines; RNA, Viral; SARS-CoV-2	2022

Article

Year

A possible interaction between favipiravir and methotrexate: Drug-induced hepatotoxicity in a patient with osteosarcoma.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:2

Favipiravir is an antiviral agent that is recently used for SARS-CoV2 infection. The drug-drug interactions of favipiravir especially with chemotherapeutic agents in a patient with malignancy are not well known.. Favipiravir may inhibit methotrexate elimination by inhibiting aldehyde oxidase and its sequential use may cause hepatotoxicity in this case. The clinicians should keep in mind possible drug interactions while using new antiviral agents against SARS-CoV2 like favipiravir.

Topics: Amides; Antiviral Agents; Bone Neoplasms; Chemical and Drug Induced Liver Injury; COVID-19; Humans; Methotrexate; Osteosarcoma; Pharmaceutical Preparations; Pyrazines; RNA, Viral; SARS-CoV-2

2022